Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing
|
By LabMedica International staff writers Posted on 08 Oct 2024 |

Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. This is especially valuable in remote or underserved regions where access to laboratory resources is limited. By enabling immediate clinical decisions, point-of-care testing can alleviate strain on healthcare systems and enhance patient outcomes. Now, a new study has demonstrated the effectiveness of a smartphone-enabled, paper-based quantitative diagnostic platform, which improves point-of-care diagnostics by delivering enhanced accuracy, real-time data, and broader accessibility for fast and reliable testing.
The study focused on HueDx’s (Pennsylvania, PA, USA) innovative platform, which comprises HueTools and HueLab. HueDx’s HueTools are artificial intelligence (AI) tools that shorten assay development from years to months while its HueLab customizable cartridge and app, create a portable testing solution that eliminates the need for a traditional lab. This research represents a significant breakthrough in colorimetric diagnostic methods, overcoming past challenges in achieving accurate and consistent results in clinical chemistry at the point of care without requiring additional hardware. The incorporation of smartphone technology enhances these capabilities, allowing for the quantification of previously qualitative assays and enabling real-time data collection and analysis. This will expand point-of-care testing to more providers, including at-home testing, delivering quantitative and actionable results.
The study found that the color correction system restored images to near-perfect consistency, independent of original illumination conditions. In precision testing, the coefficient of variation was nearly twice as high without the color correction. Additionally, limits of blank, detection, and quantification were significantly improved using the HueDx pipeline. The research also demonstrated the platform's effectiveness in calibrating and quantifying a paper-based total protein assay, illustrating its potential for use in point-of-care testing across diverse medical settings.
“The HueDx color correction system represents a major leap forward in diagnostic technology, allowing for accurate and reliable testing in real-world settings,” said Dr. Nidhi Menon, Head of R&D, at HueDx, Inc. “We’re dedicated to enhancing health outcomes with innovative solutions, and our work truly reflects that commitment, setting the stage for the future of smartphone-enabled diagnostics.”
Related Links:
HueDx
Latest Clinical Chem. News
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
- Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
- Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Channels
Clinical Chemistry
view channel
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read moreMolecular Diagnostics
view channel
AI-Powered Blood Test Detects Early Pancreatic Cancer with More Than 90% Accuracy
Pancreatic cancer is one of the most lethal cancers, often referred to as the “King of Cancers” because symptoms usually appear only at advanced stages. As a result, most patients are diagnosed late, and... Read more
AI-Powered Blood Test Flags Relapse Risk Earlier After Transplant
Relapse after allogeneic hematopoietic cell transplant is a major cause of mortality in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and standard monitoring can miss early warning signals.... Read more
World’s First Portable POC Test Simultaneously Detects Four Common STIs in One Hour
Sexually transmitted infections (STIs) often present with similar symptoms, making accurate diagnosis challenging without laboratory testing. Delays in identifying the exact infection can lead to inappropriate... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
New Imaging Approach Could Help Predict Dangerous Gut Infection
Clostridioides difficile infections affect roughly half a million people in the United States each year and are a leading cause of infectious diarrhea in healthcare settings. The bacterium can trigger... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








